Core Insights - Monopar Therapeutics Inc. is presenting new data from the Phase 2 ALXN1840-WD-204 copper balance study at the AASLD conference, highlighting the company's focus on innovative treatments for unmet medical needs [1][2] Study Findings - The oral presentation by Professor Aftab Ala indicates that treatment with ALXN1840 (tiomolybdate choline) resulted in a rapid and sustained improvement in daily copper balance in Wilson disease patients, primarily through increased fecal copper excretion [2] - The mean daily copper balance among patients treated with ALXN1840 (n=8) showed significant improvement compared to pre-treatment baseline, with positive results observed during both the initial 15 mg once-daily dosing period (days 1-28) and the entire treatment duration (days 1-39) [3] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company with a focus on late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs, including MNPR-101-Zr for imaging advanced cancers and MNPR-101-Lu and MNPR-101-Ac225 for treating advanced cancers [5]

Core Insights - Monopar Therapeutics Inc. announced new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease, to be presented at the 150th American Neurological Association Annual Meeting [1][3] Group 1: Efficacy and Safety Data - The analysis pooled efficacy outcomes from three independent clinical trials involving 255 patients, while safety data included a fourth independent clinical trial with 266 patients [2] - Median treatment duration with ALXN1840 was approximately 2.6 years for both efficacy and safety analyses [2] - Statistically significant neurological improvement was sustained over 6 years on the Unified Wilson Disease Rating Scale [6] - Patients who crossed over from standard of care to ALXN1840 showed additional neurological improvement, with many reversing worsened conditions [6] - Statistically significant psychiatric improvement was also sustained over multiple years, measured by the Brief Psychiatric Rating Scale [6] - Neurological benefits were consistently observed across multiple independent studies [6] - The safety profile of ALXN1840 was favorable, with less than 1% of patients experiencing drug-related neurological serious adverse events over more than 645 patient-years [6] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including ALXN1840 for Wilson disease and various radiopharmaceutical programs [4]

Core Insights - Monopar Therapeutics Inc. announced new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease, to be presented at the 150th American Neurological Association Annual Meeting [1][3] - The analysis pooled efficacy outcomes from three independent clinical trials involving 255 patients, while safety data included a fourth independent clinical trial with 266 patients, with a median treatment duration of approximately 2.6 years [2] Efficacy and Safety Findings - Long-term neurological benefits of ALXN1840 were highlighted, showing sustained improvement on the Unified Wilson Disease Rating Scale (UWDRS) over 6 years [6] - Patients who switched from standard of care to ALXN1840 experienced additional neurological improvements, with many reversing previous declines [6] - Statistically significant psychiatric improvements were also sustained over multiple years, measured by the Brief Psychiatric Rating Scale (BPRS) [6] - Neurological benefits were consistently observed across multiple independent studies [6] - The safety profile of ALXN1840 was favorable, with less than 1% of patients experiencing drug-related serious adverse events over more than 645 patient-years [6] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including ALXN1840 for Wilson disease and various radiopharmaceutical programs [4]

Core Insights - Monopar Therapeutics Inc. announced that its abstract on the long-term neurological benefits of ALXN1840 in Wilson disease patients has been selected for both oral and poster presentations at the 150th American Neurological Association Annual Meeting [1][2] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs [3] Presentation Details - The abstract titled "Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline" has been designated as an Abstract of Distinction by the ANA [2] - The poster presentation is scheduled for September 14, 2025, and the oral presentation for September 15, 2025 [5]

Core Viewpoint - Monopar Therapeutics Inc. has announced that data on the long-term efficacy and safety of its drug candidate ALXN1840 for Wilson disease will be presented at the EASL International Liver Congress 2025, highlighting the significance of this research in the hepatology field [1][2]. Group 1: Presentation Details - The late-breaker poster presentation will focus on "Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline" [3]. - The presentation is scheduled for May 7, 2025, at 8:30 a.m. CET, and will be led by Dr. Karl Heinz Weiss [3]. - The poster will be available online on the company's website on the same day [3]. Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biotechnology company with a focus on developing innovative treatments, including ALXN1840 for Wilson disease and various radiopharmaceutical programs for advanced cancers [4].